Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator. The PHP Study. (PHP)

Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator (ICD) During Dual Antiplatelet or Anticoagulant Therapy. A Prospective Randomized Trial. The PHP Study.

The aim of this study is to demonstrate the efficacy of fibrin sealant (Tissucol-Baxter) in preventing pocket haematoma and subsequent complications in patients undergoing pacemaker or ICD implantation/replacement which cannot discontinue dual antiplatelet therapy (i.e. ASA and clopidogrel, ASA and prasugrel) or anticoagulant therapy (i.e. warfarin, heparin, low molecular weight heparin).

Fibrin-based sealant is available for local haemostasis. A recent study (Milic DJ et al, 2005 Europace, 7: 374-379) has shown the efficacy of the fibrin sealant in prevention of pacemaker pocket haematoma in 40 patients undergoing pacemaker implantation who are receiving anticoagulant treatment.

Patients with dual antiplatelet therapy (DAT) are prone to a high risk of bleeding during surgical procedures. Thus, the routine use is the discontinuation of DAT al least 4-7 days before the intervention. This practice may result in a high risk of thrombotic events in patients with coronary stenting.

Recently, in our Center we started the use of a fibrin sealant for local haemostasis (Tissucol Baxter), and the investigators observed a reduction in the incidence of pocket haematoma complication, the need of vacuum drainage system, and the reduction of hospital stay.

Study Overview

• Status: Completed
• Conditions: Pacemaker Implantation; Pocket Hematoma and Bleeding; Antiplatelet Therapy or Oral Anticoagulants
• Intervention / Treatment: Drug: tissucol; Procedure: drainage system

Detailed Description

Purpose of the study. The purpose of this study is to demonstrate the efficacy of a fibrin sealant (Tissucol-Baxter) in prevention pocket haematoma and subsequent complications in patients who required implantation/replacement of a pacemaker or ICD wich cannot discontinue dual antiplatelet or anticoagulant therapy.

Target. The primary endpoint is to test the impact of pocket haematoma in patients treated with tissucol compared to a conventional treatment with vacuum drainage system without dual antiplatelet or anticoagulant therapy discontinuation.

The secondary endpoint is to compare the length of hospitalization between the two groups.

Type of study. Prospective, randomized, single center, open label.

Materials and methods. Will be consecutively enrolled approximately 100 patients.

Inclusion criteria: patients over the age of eighteen who require an initial implantation or replacement of a device (pacemaker, biventricular pacemaker, ICD) treated with:

• dual antiplatelet therapy (clopidogrel or prasugrel or ticlopidine, and acetylsalicylic acid) or
• anticoagulants (warfarin or heparin or low molecular weight heparin). Patients Do not discontinue the antiplatelet or anticoagulant therapy.

According to a randomization list, patients will be assigned to tissucol treatment or vacuum drainage system:

• 50 patients: treated with local application of tissucol in the pocket of pacemaker/ICD;
• 50 patients: treated with vacuum drainage system.

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Phase 4

Contacts and Locations

Study Locations

• Italy
  • Florence, Italy, 50134
    • Division of Invasive Cardiology 1, Careggi Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients who require an initial implantation or replacement of a device (pacemaker, biventricular pacemaker, implantable cardiac defibrillator) treated with:

  • Dual antiplatelet therapy (i.e. ASA and clopidogrel, ASA and prasugrel) or
  • Anticoagulant therapy (warfarin, heparin, LMWH).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: treatment with tissucol; patients treated with tissucol, local application in the pocket of PM / ICD	Drug: tissucol; dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes; Other Names: local tissucol application
ACTIVE_COMPARATOR: vacuum drainage system; patients treated with application of vacuum drainage system.	Procedure: drainage system; application of vacuum drainage system; Other Names: vacuum drainage system

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Complications of pocket device: haematoma and bleeding.Pocket haematoma is defined as palpable swelling of the device pocket exceeding the size of the generator.Bleeding is defined as > 100 ml amount of fluid collected in the drainage system.	45 days after intervention

Secondary Outcome Measures

Outcome Measure	Time Frame
The duration of the hospital stay	45 days after intervention
The number of outpatient visits following the hospitalization	45 days after intervention

Collaborators and Investigators

• Sponsor: Careggi Hospital
• Investigators: Principal Investigator: Emilio V Dovellini, MD, Division of Invasive Cardiology, Careggi Hospital

Study record dates

Study Major Dates

• Study Start: December 1, 2009
• Primary Completion (ACTUAL): January 1, 2011
• Study Completion (ACTUAL): January 1, 2011

Study Registration Dates

• First Submitted: May 20, 2010
• First Submitted That Met QC Criteria: May 20, 2010
• First Posted (ESTIMATE): May 21, 2010

Study Record Updates

• Last Update Posted (ESTIMATE): February 11, 2011
• Last Update Submitted That Met QC Criteria: February 10, 2011
• Last Verified: May 1, 2010

More Information

Terms related to this study

• Keywords: pacemaker; antiplatelet therapy; fibrin glue; pocket haematoma
• Additional Relevant MeSH Terms: Pathologic Processes; Hemorrhage; Hematoma; Hemostatics; Coagulants; Fibrin Tissue Adhesive
• Other Study ID Numbers: DOVE 1